Strong growth across multiple cancer indications as well as price rises saw Merck & Co’s PD-1 inhibitor Keytruda (pembrolizumab) increase its revenues by 18% in 2024, putting it more than $12bn ahead of its closest rival for the position of best-selling drug globally.
The GLP-1 inhibitors continued to exert their force over the global medicines market. Novo Nordisk’s Ozempic (semaglutide) for type 2 diabetes grew by 26% to reach second place at the same time as Eli Lilly’s more recently launched competitor Mounjaro (tirzepatide) more than doubled its annual sales and entered the top 20 for the first time in eighth position
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?